EGF-IL-18 fusion protein as a potential anti-tumor reagent by induction of immune response and apoptosis in cancer cells

Cancer Letters

Volumn 260, Issue 1-2, 2008, Pages 187-197

  Lu, Jianxin ^a,c   Peng, Y ^a   Zheng, Z J ^a   Pan, J H ^a   Zhang, Yangde ^c   Bai, Yidong ^a,b  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Anti cancer; Apoptosis; Epidermal growth factor (EGF); Fusion protein; Interleukin 18 (IL 18)

Indexed keywords

COMPLEMENTARY DNA; CONCANAVALIN A; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; HYBRID PROTEIN; INTERLEUKIN 18; RECOMBINANT INTERLEUKIN 18;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELL CYCLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN PURIFICATION; SOLID TUMOR; TUMOR IMMUNOLOGY; TUMOR REGRESSION; WESTERN BLOTTING; X IRRADIATION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; G1 PHASE; HUMANS; IMMUNE SYSTEM; INTERFERON TYPE II; INTERLEUKIN-18; K562 CELLS; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LIVER NEOPLASMS, EXPERIMENTAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, NUDE; PEPTIDES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TIME FACTORS; VIRAL FUSION PROTEINS; X-RAYS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 38349056501     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.10.042     Document Type: Article

References (40)

1. Nakamura K., Okamura H., Wada M., Nagata K., and Tamura T. Endotoxin-induced serum factor that stimulates gamma interferon production. Infect. Immun. 57 (1989) 590-595
2. Gracie J.A., Robertson S.E., and McInnes I.B. Interleukin-18. J. Leukoc. Biol. 73 (2003) 213-224
3. Ohtsuki T., Micallef M.J., Kohno K., Tanimoto T., Ikeda M., and Kurimoto M. Interleukin 18 enhances Fas ligand expression and induces apoptosis in Fas-expressing human myelomonocytic KG-1 cells. Anticancer Res. 17 (1997) 3253-3258
4. Lissoni P., Brivio F., Rovelli F., Fumagalli G., Malugani F., Vaghi M., Secondino S., Bucovec R., and Gardani G.S. Serum concentrations of interleukin-18 in early and advanced cancer patients: enhanced secretion in metastatic disease. J. Biol. Regul. Homeost. Agents 14 (2000) 275-277
5. Herbst R.S. Targeted therapy in non-small-cell lung cancer. Oncology (Williston Park) 16 (2002) 19-24
6. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr. Relat. Cancer 8 (2001) 3-9
7. Mendelsohn J., and Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 21 (2003) 2787-2799
8. Nicholson R.I., Gee J.M., and Harper M.E. EGFR and cancer prognosis. Eur. J. Cancer 37 Suppl. 4 (2001) S9-S15
9. Nestor Jr. J.J., Newman S.R., DeLustro B., Todaro G.J., and Schreiber A.B. A synthetic fragment of rat transforming growth factor alpha with receptor binding and antigenic properties. Biochem. Biophys. Res. Commun. 129 (1985) 226-232
10. Chen W.Q., Ding Y.P., Zhang L.L., and Hou Y.D. Enhanced anti-tumor effect of an IFN-gamma-EGF fusion protein. Biomed. Environ. Sci. 10 (1997) 387-395
11. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
12. Lu J.X., Peng Y., Meng Z.F., Jin L.Q., Lu Y.S., and Guan M.X. Rational design of an EGF-IL18 fusion protein: implication for developing tumor therapeutics. Biochem. Biophys. Res. Commun. 334 (2005) 157-161
13. Chen J.J., Sun M., Lu F., Chen C.Q., and Wang D.B. Construction and Expression of hTNFalpha-hTGF3 Fused Gene. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 31 (1999) 513-518
14. Micallef M.J., Yoshida K., Kawai S., Hanaya T., Kohno K., Arai S., Tanimoto T., Torigoe K., Fujii M., Ikeda M., and Kurimoto M. In vivo antitumor effects of murine interferon-gamma-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites. Cancer Immunol. Immunother. 43 (1997) 361-367
15. Osaki T., Peron J.M., Cai Q., Okamura H., Robbins P.D., Kurimoto M., Lotze M.T., and Tahara H. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects. J. Immunol. 160 (1998) 1742-1749
16. Gutzmer R., Langer K., Mommert S., Wittmann M., Kapp A., and Werfel T. Human dendritic cells express the IL-18R and are chemoattracted to IL-18. J. Immunol. 171 (2003) 6363-6371
17. Kaser A., Kaser S., Kaneider N.C., Enrich B., Wiedermann C.J., and Tilg H. Interleukin-18 attracts plasmacytoid dendritic cells (DC2s) and promotes Th1 induction by DC2s through IL-18 receptor expression. Blood 103 (2004) 648-655
18. Komai-Koma M., Gracie J.A., Wei X.Q., Xu D., Thomson N., McInnes I.B., and Liew F.Y. Chemoattraction of human T cells by IL-18. J. Immunol. 170 (2003) 1084-1090
19. Cumberbatch M., Dearman R.J., Antonopoulos C., Groves R.W., and Kimber I. Interleukin (IL)-18 induces Langerhans cell migration by a tumour necrosis factor-alpha- and IL-1beta-dependent mechanism. Immunology 102 (2001) 323-330
20. Delvenne P., al-Saleh W., Gilles C., Thiry A., and Boniver J. Inhibition of growth of normal and human papillomavirus-transformed keratinocytes in monolayer and organotypic cultures by interferon-gamma and tumor necrosis factor-alpha. Am. J. Pathol. 146 (1995) 589-598
21. Jia S.F., and Kleinerman E.S. Antitumor activity of TNF-alpha, IL-1, and IFN-gamma against three human osteosarcoma cell lines. Lymphokine Cytokine Res. 10 (1991) 281-284
22. Palumbo A., Battaglio S., Napoli P., Omede P., Fusaro A., Bruno B., Boccadoro M., and Pileri A. Recombinant interferon-gamma inhibits the in vitro proliferation of human myeloma cells. Br. J. Haematol. 86 (1994) 726-732
23. Rubin B.Y., and Gupta S.L. Differential efficacies of human type I and type II interferons as antiviral and antiproliferative agents. Proc. Natl. Acad. Sci. USA 77 (1980) 5928-5932
24. Watanabe Y., Kuribayashi K., Miyatake S., Nishihara K., Nakayama E., Taniyama T., and Sakata T. Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc. Natl. Acad. Sci. USA 86 (1989) 9456-9460
25. Boehm U., Klamp T., Groot M., and Howard J.C. Cellular responses to interferon-gamma. Annu. Rev. Immunol. 15 (1997) 749-795
26. Arenberg D.A., Kunkel S.L., Polverini P.J., Morris S.B., Burdick M.D., Glass M.C., Taub D.T., Iannettoni M.D., Whyte R.I., and Strieter R.M. Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J. Exp. Med. 184 (1996) 981-992
27. Harvat B.L., and Jetten A.M. Gamma-interferon induces an irreversible growth arrest in mid-G1 in mammary epithelial cells which correlates with a block in hyperphosphorylation of retinoblastoma. Cell Growth Differ. 7 (1996) 289-300
28. Kominsky S., Johnson H.M., Bryan G., Tanabe T., Hobeika A.C., Subramaniam P.S., and Torres B. IFNgamma inhibition of cell growth in glioblastomas correlates with increased levels of the cyclin dependent kinase inhibitor p21WAF1/CIP1. Oncogene 17 (1998) 2973-2979
29. Ruemmele F.M., Gurbindo C., Mansour A.M., Marchand R., Levy E., and Seidman E.G. Effects of interferon gamma on growth, apoptosis, and MHC class II expression of immature rat intestinal crypt (IEC-6) cells. J. Cell Physiol. 176 (1998) 120-126
30. Subramaniam P.S., and Johnson H.M. A role for the cyclin-dependent kinase inhibitor p21 in the G1 cell cycle arrest mediated by the type I interferons. J. Interferon Cytokine Res. 17 (1997) 11-15
31. Vadiveloo P.K., Vairo G., Novak U., Royston A.K., Whitty G., Filonzi E.L., Cragoe Jr. E.J., and Hamilton J.A. Differential regulation of cell cycle machinery by various antiproliferative agents is linked to macrophage arrest at distinct G1 checkpoints. Oncogene 13 (1996) 599-608
32. Tamura T., Ueda S., Yoshida M., Matsuzaki M., Mohri H., and Okubo T. Interferon-gamma induces Ice gene expression and enhances cellular susceptibility to apoptosis in the U937 leukemia cell line. Biochem. Biophys. Res. Commun. 229 (1996) 21-26
33. Arany I., Brysk M.M., Calhoun K.H., and Tyring S.K. Differentiation and IFN gamma regulate WAF1/CIP1 transcription in p53-independent and p53-dependent pathways in epithelial cells. In Vivo 10 (1996) 119-123
34. Xaus J., Cardo M., Valledor A.F., Soler C., Lloberas J., and Celada A. Interferon gamma induces the expression of p21waf-1 and arrests macrophage cell cycle, preventing induction of apoptosis. Immunity 11 (1999) 103-113
35. Cohen G.M. Caspases: the executioners of apoptosis. Biochem. J. 326 Pt 1 (1997) 1-16
36. Harvat B.L., Seth P., and Jetten A.M. The role of p27Kip1 in gamma interferon-mediated growth arrest of mammary epithelial cells and related defects in mammary carcinoma cells. Oncogene 14 (1997) 2111-2122
37. Wolf B.B., and Green D.R. Suicidal tendencies: apoptotic cell death by caspase family proteinases. J. Biol. Chem. 274 (1999) 20049-20052
38. Nagata S. Apoptosis by death factor. Cell 88 (1997) 355-365
39. Nagata S. Fas-induced apoptosis. Intern. Med. 37 (1998) 179-181
40. Dighe A.S., Richards E., Old L.J., and Schreiber R.D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1 (1994) 447-456